Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S B Kim

Showing results (211-220 of 512) with videos related to

Pageof 52
Sort By:
Oncogenesis|April 5, 2016
BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancerC Gong, S Yao, A R Gomes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2024
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastasesF André, J Cortés, G Curigliano, et al.
Brain : a Journal of Neurology|July 13, 2006
Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutationsK W Chung, S B Kim, K D Park, et al.
British Journal of Cancer|August 25, 2012
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survivalY S Yap, G H Cornelio, B C R Devi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast CancerB Xu, H Jeong, T Sun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trialY Guo, M-J Ahn, A Chan, et al.
HIV Medicine|March 4, 2014
HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS ProjectN S Ku, Y Lee, J Y Ahn, et al.
Antonie Van Leeuwenhoek|November 3, 2011
Phylogenetic study of the species within the family StreptomycetaceaeD P Labeda, M Goodfellow, R Brown, et al.
ESMO Open|May 25, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trialS A Hurvitz, S-B Kim, W-P Chung, et al.
ESMO Open|June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-BF Marmé, M Martin, M Untch, et al.
Pageof 52

Showing results (211-220 of 512) with videos related to

Sort By:
Pageof 52
Oncogenesis|April 5, 2016
BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancerC Gong, S Yao, A R Gomes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2024
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastasesF André, J Cortés, G Curigliano, et al.
Brain : a Journal of Neurology|July 13, 2006
Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutationsK W Chung, S B Kim, K D Park, et al.
British Journal of Cancer|August 25, 2012
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survivalY S Yap, G H Cornelio, B C R Devi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2026
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast CancerB Xu, H Jeong, T Sun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trialY Guo, M-J Ahn, A Chan, et al.
HIV Medicine|March 4, 2014
HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS ProjectN S Ku, Y Lee, J Y Ahn, et al.
Antonie Van Leeuwenhoek|November 3, 2011
Phylogenetic study of the species within the family StreptomycetaceaeD P Labeda, M Goodfellow, R Brown, et al.
ESMO Open|May 25, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trialS A Hurvitz, S-B Kim, W-P Chung, et al.
ESMO Open|June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-BF Marmé, M Martin, M Untch, et al.
Pageof 52